Dr Dennis Wright

BPharm MSc PhD

Vice President, Scientific Affairs

Dr Wright has a broad range of experience in the pharmaceutical industry spanning 25 years. He spent more than 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager.

During this time Dr Wright was responsible for the registration of a number of key products in Australia and the management of regulatory strategy for development projects.

Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, a company recently acquired by Halcygen (ASX:HGN).

He has a Pharmacy degree and post-graduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne. Dr Wright is responsible for leading the clinical and regulatory development team and progressing afamelanotide through to regulatory approval in global markets.

Investors Related Blog Posts

Image

MAA: a moment in Clinuvel’s EPP...

Those who have taken an interest in Clinuvel will have learned with joy that, on Monday February 6th, the... Read more...

Image

Online evolution...

Earlier this week we unveiled a major update to our online presence with the release of our new-look website... Read more...

Image

EPP results and clinical relevanc...

Over recent months I have written several times of the need for Clinuvel to prove clinical relevance in... Read more...

Investors Related Videos

Part Four - The impact of Eryt...

Mikey's quality of life, like all patients with Erythropoietic Protoporphyria (EPP), is severely affected. Severe pain f... Watch now

Quick! I need Sunburn Relief! ...

There are many remedies available to help provide relief from the symptoms of sunburn. Treatment of sunburn can include:... Watch now

Understanding Vitiligo - Cause...

Vitiligo is a common pigmentary disorder in which the pigment producing cells of the skin (melanocytes) are absent or do... Watch now

JoomlaXTC K2 Content Wall - Copyright 2010 Monev Software LLC

Featured Content

Annual Report for the year ended 30 June 2011

Contents: INTRODUCTION | ERYTHROPOIETIC PROTOPORPHYRIA (EPP) | NONSEGMENTAL VITILIGO (NSV) | CLINUVEL BUSINESS MODEL | CORPORATE MILESTONES | CHAIR's LETTER | MANAGING DIRECTOR’S REPORT | FINANCIALS | ADDITIONAL INFORMATION REQUIRED BY THE ASX | MA... Read more

JoomlaXTC K2 Content Wall - Copyright 2010 Monev Software LLC